Effect of high-dose methylprednisolone treatment on CCR5 expression on blood cells in MS exacerbation

Acta Neurologica Scandinavica

Volumn 113, Issue 3, 2006, Pages 163-166

  Elovaara, I ^a,b   Kuusisto, H ^b   Paalavuo, R ^a   Sarkijarvi S ^a   Lehtimaki T ^a,b   Huhtala, H ^a   Vilpo, J ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Chemokine receptor 5; Methylprednisolone; Multiple sclerosis

Indexed keywords

CD14 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR5; METHYLPREDNISOLONE;

ADULT; ARTICLE; BLOOD CELL; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MIGRATION; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DRUG MECHANISM; DRUG MEGADOSE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; MONOCYTE; MULTIPLE SCLEROSIS; PROTEIN EXPRESSION;

ADULT; ANTI-INFLAMMATORY AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL MOVEMENT; CENTRAL NERVOUS SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MULTIPLE SCLEROSIS; RECEPTORS, CCR5;

EID: 33645227147     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2005.00566.x     Document Type: Article

References (20)

1. L assmann H R aine CS A ntel J Prineas JW. Immunopathology of multiple sclerosis: report on an international meeting held at the Institute of Neurology of the University of Vienna. J Neuroimmunol 1998 86 213 7.
2. D urelli L C ocito D R iccio A et al. High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations. Neurology 1986 36 238 43.
3. M illigan NM N ewcombe R C ompston DA. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry 1987 50 511 6.
4. P ozzilli C M arinelli F R omano S Bagnato F. Corticosteroids treatment. J Neurol Sci 2004 223 47 51.
5. B arkhof F F requin ST H ommes OR et al. A correlative triad of gadolinium-DTPA MRI, EDSS, and CSF-MBP in relapsing multiple sclerosis patients treated with high-dose intravenous methylprednisolone. Neurology 1992 42 63 7.
6. N os C S astre -G arriga J B orras C et al. Clinical impact of intravenous methylprednisolone in attacks of multiple sclerosis. Mult Scler 2004 10 413 6
7. M oser B W olf M W alz A Loetscher P. Chemokines: multiple levels of leukocyte migration control. Trends Immunol 2004 25 75 84.
8. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998 392 565 8.
9. L oetscher P U guccioni M B ordoli L et al. CCR5 is characteristic of Th1 lymphocytes. Nature 1998 391 344 5.
10. D 'Ambrosio D P anina -B ordignon P Sinigaglia F. Chemokine receptors in inflammation: an overview. J Immunol Methods 2003 273 3 13.
11. B alashov KE R ottman JB W einer HL Hancock WW. CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci U S A 1999 96 6873 8.
12. S orensen TL T ani M J ensen J et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 1999 103 807 15.
13. J alonen TO P ulkkinen K U kkonen M S aarela M Elovaara I. Differential intracellular expression of CCR5 and chemokines in multiple sclerosis subtypes. J Neurol 2002 249 576 83.
14. N akajima H F ukuda K D oi Y et al. Expression of TH1/TH2-related chemokine receptors on peripheral T cells and correlation with clinical disease activity in patients with multiple sclerosis. Eur Neurol 2004 52 162 8.
15. P oser CM P aty DW S cheinberg L et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983 13 227 31.
16. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983 33 1444 52.
17. M artinez -C aceres EM B arrau MA B rieva L E spejo C B arbera N Montalban X. Treatment with methylprednisolone in relapses of multiple sclerosis patients: immunological evidence of immediate and short-term but not long-lasting effects. Clin Exp Immunol 2002 127 165 71.
18. Butler WT. Corticosteroids and immunoglobulin synthesis. Transplant Proc 1975 7 49 53.
19. Dietrich JB. Endothelial cells of the blood-brain barrier: a target for glucocorticoids and estrogens Front Biosci 2004 9 684 93.
20. A lmawi WY B eyhum HN R ahme AA Rieder MJ. Regulation of cytokine and cytokine receptor expression by glucocorticoids. J Leukoc Biol 1996 60 563 72.